Key Points
- CEO Katherine Stueland sold 46,933 shares on March 26 at $63.17 for $2.965M and, including prior sales on March 16, March 4 and Jan 29, has sold about 91,224 shares year-to-date for roughly $6.44M, cutting her ownership by 33.9% to 91,514 shares.
- Despite the insider selling, GeneDx beat quarterly EPS estimates ($0.14 vs. $0.11) with revenue roughly in line at $120.99M, and analysts maintain a consensus "Moderate Buy" rating with an average price target of $140.71.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 46,933 shares of the stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $63.17, for a total transaction of $2,964,757.61. Following the sale, the chief executive officer owned 91,514 shares in the company, valued at approximately $5,780,939.38. This trade represents a 33.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Katherine Stueland also recently made the following trade(s):
- On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total transaction of $1,319,347.20.
- On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The stock was sold at an average price of $78.61, for a total transaction of $2,001,331.99.
- On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The stock was sold at an average price of $94.00, for a total value of $155,382.00.
GeneDx Stock Up 1.0%
Shares of NASDAQ WGS opened at $66.20 on Friday. The stock has a market cap of $1.94 billion, a P/E ratio of -88.27 and a beta of 2.17. The business's fifty day simple moving average is $82.46 and its 200-day simple moving average is $114.99. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $170.87. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16.
GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The firm had revenue of $120.99 million during the quarter, compared to analysts' expectations of $120.80 million. As a group, equities analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.
Institutional Trading of GeneDx
Institutional investors have recently modified their holdings of the stock. Arizona State Retirement System boosted its holdings in shares of GeneDx by 2.1% in the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company's stock valued at $728,000 after buying an additional 113 shares in the last quarter. Cerity Partners LLC raised its stake in GeneDx by 6.0% during the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company's stock worth $329,000 after acquiring an additional 142 shares in the last quarter. Main Management ETF Advisors LLC raised its stake in GeneDx by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company's stock worth $2,037,000 after acquiring an additional 160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in GeneDx by 5.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company's stock valued at $399,000 after acquiring an additional 181 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its position in GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock valued at $25,000 after acquiring an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on WGS. Zacks Research upgraded shares of GeneDx from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 25th. Wall Street Zen lowered GeneDx from a "buy" rating to a "hold" rating in a report on Sunday, February 8th. Wells Fargo & Company upgraded GeneDx from an "equal weight" rating to an "overweight" rating and set a $155.00 price target on the stock in a research note on Monday, February 9th. Guggenheim decreased their price target on GeneDx from $170.00 to $100.00 and set a "buy" rating for the company in a report on Monday. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of GeneDx in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $140.71.
Read Our Latest Stock Report on WGS
About GeneDx
(
Get Free Report)
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
